SEATTLE, Feb.

SEATTLE, Jan. 5, 2011 /PRNewswire/ -- Omeros Corporation (Nasdaq: OMER) today announced that it has obtained an exclusive license from The Regents of the University of California to a new series of antifibrinolytic agents.

NEW YORK, Sept.

The U.S. Food and Drug Administration announced the Bayer Pharmaceuticals Corp. is removing its entire stock of the drug Trasylol from the U.S. market. Last November Bayer agreed to an FDA-requested marketing suspension of Trasylol, a drug used to control bleeding during heart surgery.

By Helen Branswell, THE CANADIAN PRESS TORONTO - An expensive drug used to minimize severe bleeding during heart surgery actually significantly increased the risk that patients would die during surgery or in the 30 days following, a Canadian study comparing the drug to two far cheaper alternatives shows.